LEARNING OBJECTIVE

After this activity, the participant will be able to demonstrate a working knowledge of potential adverse events and the subjective and objective outcomes of long-term ustekinumab treatment in patients with moderate to severe ulcerative colitis.

CASE 1

A 62-year-old man presents for follow-up 4 months after his diagnosis of moderate ulcerative pancolitis after initially presenting with bloody diarrhea. He responded to ustekinumab induction and is currently receiving ustekinumab maintenance treatment with noted symptomatic improvement. He asks about expectations for long-term ustekinumab treatment.

QUESTION 1

According to this article, through 4 years of ustekinumab treatment:

15% of patients achieved symptomatic remission and 40% had endoscopic improvement 35% of patients achieved symptomatic remission and 60% had endoscopic improvement 55% of patients achieved symptomatic remission and 80% had endoscopic improvement 75% of patients achieved symptomatic remission and 100% had endoscopic improvement QUESTION 2

Compared to patients with a history of biologic failure, biologic naïve patients with moderate to severe ulcerative colitis on long-term ustekinumab maintenance treatment are more likely to:

Discontinue treatment Achieve symptomatic remission Require corticosteroids Fail to maintain symptomatic remission QUESTION 3

Based on this article, what is the most frequent adverse event in patients receiving long-term ustekinumab maintenance treatment for moderate to severe ulcerative colitis?

Ulcerative colitis worsening Upper respiratory tract infection Nasopharyngitis Non-melanoma skin cancer